SCM
NKGNW

Saba Capital Management’s NKGen Biotech, Inc. Warrants NKGNW Stock Holding History

Saba Capital Management’s Portfolio NKGNW Stock Details NKGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-31,129
Closed -$3.5K – 294
2024
Q4 		$3.5K Hold
31,129
– – ﹤0.01% 268
2024
Q3 		$2.2K Hold
31,129
– – ﹤0.01% 338
2024
Q2 		$3.07K Hold
31,129
– – ﹤0.01% 357
2024
Q1 		$4.36K Hold
31,129
– – ﹤0.01% 364
2023
Q4 		$2.52K Hold
31,129
– – ﹤0.01% 467
2023
Q3 		$12.3K Hold
31,129
– – ﹤0.01% 482
2023
Q2 		$6.52K Hold
31,129
– – ﹤0.01% 568
2023
Q1 		$4.36K Hold
31,129
– – ﹤0.01% 731
2022
Q4 		$2.72K Hold
31,129
– – ﹤0.01% 877
2022
Q3 		$5K Buy
+31,129
New +$5.36K ﹤0.01% 1051

Other funds holding NKGNW

RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return

Saba Capital Management's NKGNW Position: Q1 2025 in Review

Saba Capital Management sold out of NKGen Biotech, Inc. Warrants (NKGNW) in Q1 2025, closing a stake of 31,129 shares — an estimated $3.5K sold.

Saba Capital Management first reported a position in NKGNW in Q3 2022 and held it in 10 quarters. The position peaked at $12.3K in Q3 2023. 3 funds tracked by Wall St. Rank hold NKGNW as of Q1 2025.

  • Saba Capital Management reported no remaining NKGen Biotech, Inc. Warrants position as of Q1 2025 after selling out during the quarter.
  • Saba Capital Management sold 31,129 NKGen Biotech, Inc. Warrants shares in Q1 2025, an estimated $3.5K.
  • Saba Capital Management first reported a position in NKGen Biotech, Inc. Warrants in Q3 2022 and held it in 10 quarters.
  • Saba Capital Management's NKGen Biotech, Inc. Warrants position peaked at $12.3K in Q3 2023.
  • 3 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Warrants as of Q1 2025.

Based on Saba Capital Management's 13F filing for Q1 2025, filed 15 May 2025.